Modified T-cell activation pattern during specific immunotherapy (SIT) in cat-allergic patients.

Area of Science:

• Immunology
• Allergy Research
• T-cell immunology

Background:

• Cat allergy is a common condition driven by T-helper 2 (TH2) immune responses.
• Specific immunotherapy (SIT) aims to re-regulate immune responses in allergic patients.
• Early immunological changes following SIT are not fully understood.

Purpose of the Study:

• To investigate the early effects of specific immunotherapy (SIT) on immune functions in patients with cat allergy.
• To analyze changes in cytokine production and T-cell subsets in response to allergen and non-specific stimuli before and after SIT.

Main Methods:

• Peripheral blood mononuclear cells (PBMCs) from eight cat-allergic patients and 11 controls were analyzed.
• Cells were stimulated with bacterial superantigen, mitogen, or cat allergen.
• Interleukin-12 (IL-12), TH1/TH2 cytokines (including IFN-gamma and IL-5), and lymphocyte subsets (CD45 RO T cells) were measured using ELISA and flow cytometry.

Main Results:

• Allergic individuals showed reduced IL-12 secretion and allergen-specific IFN-gamma production compared to controls.
• Prior to SIT, allergen- and mitogen-stimulated IL-5 production was significantly higher in allergic patients.
• Following SIT, allergen-induced IL-5 returned to normal levels, and a reduction in CD45 RO T cells was observed.

Conclusions:

• SIT demonstrates early effects on allergen-specific T-cell responses.
• SIT selectively inhibits the up-regulated TH2 immune response in cat-allergic patients.
• These findings highlight SIT's potential to modulate key immune pathways in allergy.